Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

Humaid O Al-Shamsi; Eric A Coomes; Khuloud Aldhaheri; Sadir Alrawi

doi:10.1001/jamaoncol.2020.5745

Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

JAMA Oncol. 2021 Jan 1;7(1):129-131. doi: 10.1001/jamaoncol.2020.5745.

Authors

Humaid O Al-Shamsi^{1

2

3}, Eric A Coomes⁴, Khuloud Aldhaheri⁵, Sadir Alrawi⁶

Affiliations

¹ Burjeel Oncology-Burjeel Medical City, Abu Dhabi, United Arab Emirates.
² Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
³ Emirates Oncology Society, Dubai, United Arab Emirates.
⁴ Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁶ Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.

Abstract

This cohort study examines the implementation of a microbiologic screening pilot program in Al Zahra Hospital in the United Arab Emirates for identifying presymptomatic COVID-19 in patients with cancer.

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Agents / administration & dosage*
COVID-19 / diagnosis*
COVID-19 Testing
Cohort Studies
Female
Humans
Male
Middle Aged
Neoplasms / drug therapy*
Neoplasms / virology*
SARS-CoV-2 / isolation & purification
United Arab Emirates
Young Adult

Substances

Antineoplastic Agents